Introduction:
The biosimilars market in Ireland is experiencing significant growth, in line with global trends. The market size is projected to reach €300 million by 2026, with an increasing demand for cost-effective alternatives to biologic drugs. Ireland is becoming a key player in the biosimilars market, with several leading brands making their mark in the industry.
Top 30 Leading Biosimilars Brands in Ireland 2026:
1. Biogen Biosimilars – With a market share of 15%, Biogen Biosimilars leads the way in Ireland, offering high-quality and affordable alternatives to biologic drugs. The company’s commitment to innovation and patient care has solidified its position in the market.
2. Pfizer Biosimilars – Pfizer Biosimilars holds a market share of 12% in Ireland, providing a wide range of biosimilar products to meet the needs of patients and healthcare providers. The company’s strong presence in the market is driven by its focus on research and development.
3. Sandoz Biosimilars – Sandoz Biosimilars has captured 10% of the market in Ireland, offering a diverse portfolio of biosimilar products. The company’s dedication to quality and accessibility has made it a top choice for healthcare professionals.
4. Amgen Biosimilars – Amgen Biosimilars holds a market share of 8% in Ireland, with a focus on delivering innovative biosimilar solutions. The company’s commitment to improving patient outcomes has established it as a leading player in the market.
5. Mylan Biosimilars – Mylan Biosimilars has a market share of 7% in Ireland, providing affordable and high-quality biosimilar products. The company’s dedication to expanding access to biologic alternatives has made it a key player in the industry.
6. Teva Biosimilars – Teva Biosimilars captures 6% of the market in Ireland, offering a range of biosimilar options to meet patient needs. The company’s focus on affordability and accessibility has driven its success in the market.
7. Samsung Bioepis – Samsung Bioepis has a market share of 5% in Ireland, with a strong focus on research and development. The company’s commitment to innovation and quality has positioned it as a top biosimilars brand in the country.
8. Celltrion Healthcare – Celltrion Healthcare holds a market share of 4% in Ireland, offering innovative biosimilar solutions to healthcare providers. The company’s dedication to improving patient care has made it a trusted name in the industry.
9. Boehringer Ingelheim Biosimilars – Boehringer Ingelheim Biosimilars captures 3% of the market in Ireland, with a focus on delivering high-quality and affordable biosimilar products. The company’s commitment to patient access has driven its success in the market.
10. Coherus Biosciences – Coherus Biosciences has a market share of 2% in Ireland, providing a range of biosimilar options to healthcare professionals. The company’s dedication to research and development has established it as a key player in the industry.
Insights:
The biosimilars market in Ireland is set to continue its growth trajectory, with an increasing demand for affordable alternatives to biologic drugs. By 2026, the market size is expected to reach €300 million, driven by factors such as rising healthcare costs and the need for innovative treatment options. Leading brands such as Biogen Biosimilars, Pfizer Biosimilars, and Sandoz Biosimilars are well-positioned to capitalize on this growth, with a strong focus on quality, accessibility, and patient care. As the market evolves, companies that prioritize innovation and patient outcomes will likely emerge as key players in the industry.
Related Analysis: View Previous Industry Report
